This implies that passive immunization with tau antibodies is a viable therapeutic focus on and which the CSF amount of p-tau262/356 or on the microtubule binding domain (MTBD) can function a helpful biomarker of tau pathology to observe tau therapeutics in scientific trials. I really such as degree of Handle you can obtain with in vitro paradigms